Compare CLIR & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLIR | JSPR |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 26.3M |
| IPO Year | 2011 | 2019 |
| Metric | CLIR | JSPR |
|---|---|---|
| Price | $4.47 | $0.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $20.00 | $15.50 |
| AVG Volume (30 Days) | 13.2K | ★ 720.1K |
| Earning Date | 04-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $530,000.00 | N/A |
| Revenue This Year | $34.29 | N/A |
| Revenue Next Year | $67.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $0.32 |
| 52 Week High | $7.56 | $2.87 |
| Indicator | CLIR | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 48.24 |
| Support Level | $3.75 | $0.61 |
| Resistance Level | $4.88 | $1.01 |
| Average True Range (ATR) | 0.41 | 0.10 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 63.16 | 12.84 |
ClearSign Technologies Corp is engaged in designing and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Its ClearSign Core technology has been proved to be in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial applications The company offers products that include process burners, boiler burners, flares, and ClearSign Eye. The company operates in one segment: Combustion segment. The products of the company include: Process Burners, Midstream and Power, Flares, Boiler Burners, and Sensing Technology.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.